Impact of Improving Cancer Survival on Drug-Treatment Opportunities: The Case of CML and Prostate Cancer
Earlier diagnosis and advances in treatment have reduced cancer patients’ mortality over the past decade in the mature markets. Developing markets will continue to see benefits in cancer survival. Cancer patients’ risk of recurrence has also declined dramatically. These advances will cause the coming decade to see growth in the number of people living with cancer outpace growth in the number of cases diagnosed annually in many markets.
